AZN AstraZeneca PLC
Healthcare$187.19+0.09%ClosedMarket Cap: $290.30B
As of 2026-05-26
Valuation
P/E (TTM)
30.93
PEG
0.68
P/B
6.15
P/S
4.79
EV/EBITDA
15.46
DCF Value
$564.15
FCF Yield
3.0%
Div Yield
1.7%
Margins & Returns
Gross Margin
79.7%
Operating Margin
23.5%
Net Margin
17.2%
ROE
22.4%
ROA
9.2%
ROIC
12.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $15.29B | 82.5% | $4.25B | $3.08B | $— | $2.15 |
| Q4 null | $15.50B | 79.9% | $2.98B | $2.33B | $— | — |
| FY null | $58.74B | 81.9% | $13.74B | $10.26B | $— | $1.57 |
| Q3 null | $15.19B | 81.6% | $3.58B | $2.53B | $— | $0.52 |
| Q2 null | $14.46B | 82.9% | $3.51B | $2.45B | $— | — |
| Q1 null | $13.59B | 83.5% | $3.67B | $2.92B | $— | $1.05 |
| Q4 null | $14.89B | 81.7% | $2.04B | $1.50B | $— | — |
| FY null | $54.07B | 81.1% | $10.00B | $7.04B | $— | $1.48 |
| Q3 null | $13.56B | 77.3% | $2.11B | $1.43B | $— | $0.50 |
| Q2 null | $12.94B | 83.1% | $2.75B | $1.93B | $— | — |
| Q1 null | $12.68B | 82.5% | $3.12B | $2.18B | $— | $0.99 |
| Q4 2023 | $12.02B | 80.8% | $1.23B | $960.0M | $1.22 | — |